Press Releases

October 6, 2020 at 2:30 AM EDT

Summary Toggle Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate

Recipharm, a leading contract development and manufacturing organisation (CDMO) has entered into an agreement with Arcturus Therapeutics, a leading U.S. based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities

PDF Version
October 5, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

LUNAR® lipids undetectable in plasma 48 hours following drug administration ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4 Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4 SAN DIEGO --(BUSINESS WIRE)--Oct.

PDF Version
October 1, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference

SAN DIEGO --(BUSINESS WIRE)--Oct. 1, 2020-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
September 8, 2020 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
September 4, 2020 at 10:31 AM EDT

Summary Toggle Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate

Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100% protection against SARS-CoV-2 infection following a single vaccination Clinical study remains on track, initial data readout expected Q4 2020 SAN DIEGO , Sept.

PDF Version
August 18, 2020 at 9:00 AM EDT

Summary Toggle Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health

SAN DIEGO , Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
August 11, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study

Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose Clinical study data expected in Q4 2020 SAN DIEGO , Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage

PDF Version
August 10, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update

COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School ; Dosing anticipated imminently, initial data expected Q4 ARCT-810 (LUNAR-OTC), mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency, Phase 1

PDF Version
August 6, 2020 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer

Nationally recognized leader in corporate life sciences transactions SAN DIEGO , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease

PDF Version
August 4, 2020 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020

SAN DIEGO , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version